依普利酮的购买渠道有哪些？

Eplerenone is a commonly used drug for high blood pressure or heart failure. It also has major adverse reactions to the human body's kidneys and electrolytes. Therefore, its use must strictly follow the doctor's instructions and be carried out under professional medical guidance.

What are the purchasing channels for eplerenone

Through legal purchasing channels, most of them can be purchased in pharmacies of major hospitals, physical pharmacies, and online drug sales platforms with corresponding qualifications.

In order to avoid medication risks caused by purchasing through informal channels, it is recommended to obtain eplerenone through formal channels.

1. Hospital Pharmacy

Patients can obtain a prescription from a doctor at the cardiovascular department or related specialist outpatient clinic, and purchase eplerenone directly at the pharmacy within the hospital with the prescription. In this way, the source of medicines is reliable, and pharmacists can provide preliminary medication guidance.

2. Physical chain pharmacies

Large chain pharmacies are equipped with a special prescription drug area. Patients with legal and valid prescriptions can purchase the required drugs in the prescription drug area in the store.

3. Compliance online platform

In recent years, many Internet hospitals and compliant pharmaceutical e-commerce platforms have provided online consultation and prescription issuance services. Patients can upload medical records through the platform, and after evaluation by doctors, electronic prescriptions will be issued and delivered to designated addresses.

The pictures come from public channels (such as the official website of the FDA, the official website of the original drug manufacturer, etc.) and are for reference only.

Global marketing status of eplerenone

Eplerenone was developed by Pfizer of the United States and was first approved for marketing in the United States in 2002 under the trade name Inspra. It has since been approved in many countries and regions including the European Union, Canada, and Australia for clinical treatment of heart failure and hypertension.

1. U.S. market

The U.S. FDA has approved eplerenone for the treatment of heart failure and hypertension after myocardial infarction, making it the first country in the world to market it. This drug is recommended in multiple clinical guidelines and is widely used.

2. European market

The European Medicines Agency (EMA) approved the marketing of eplerenone in 2003. It is used as a cardiovascular and cerebrovascular treatment drug in many EU member states, and can also be reimbursed through medical insurance in some countries.

3. Asia and other regions

Japan, China and other Asian countries have also approved the marketing of eplerenone. In China, eplerenone is a drug reimbursed by medical insurance, and patients can enjoy medical insurance payment if they meet the indications.

Eplerenone medication precautions

Due to the aldosterone antagonism of eplerenone, its clinical application will inevitably cause a series of side effects, such as a greater impact on potassium ions, which can easily cause hyperkalemia. Therefore, monitoring its serum potassium is particularly important.

1. Serum potassium monitoring and dose adjustment

Serum potassium levels should be tested regularly before and during medication to avoid serious consequences such as arrhythmia. When the patient's serum potassium level reaches 5.5mEq/L, the medication should be suspended promptly and the drug dosage should be adjusted accordingly according to the actual situation.

2. Contraindications and special groups

It is contraindicated in patients with severe renal insufficiency (creatinine clearance ≤30 mL/min), patients with existing hyperkalemia, or patients who are concurrently using strong CYP3A4 inhibitors (such as ketoconazole).

The elderly and patients with diabetes should use it with caution and strengthen monitoring.

3. Drug interactions

The combined use of eplerenone with ACEI, ARB, NSAIDs and other drugs may increase the risk of hyperkalemia. When combined with a moderate CYP3A4 inhibitor, the dose needs to be reduced accordingly.